Steven N. Gordon

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.

Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach.

Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach.

Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach.

Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach.

Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach.